GIBF

Silexion Therapeutics is a biotechnology company dedicated to developing treatments for KRAS-driven cancers, with a particular emphasis on pancreatic cancer. The company's lead product, SIL-204, is a small interfering RNA (siRNA) therapy delivered in an extended-release formulation aimed at treating locally advanced pancreatic cancer. Silexion is actively working on enhancing its product offerings and is planning further clinical trials to improve treatment outcomes for patients with specific KRAS mutations. Through its innovative approach and focus on clinical efficacy, Silexion aims to address significant unmet medical needs in oncology.

BioVersys AG is a biopharmaceutical company based in Basel that specializes in the research and development of innovative drugs aimed at overcoming drug resistance in bacterial pathogens. The company is dedicated to addressing the pressing global health challenge of multidrug-resistant bacterial infections by restoring the effectiveness of existing antibiotics. BioVersys utilizes its proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform to discover new therapies that inhibit bacterial resistance mechanisms. This approach not only targets novel bacterial pathways but also provides healthcare professionals with new treatment options for patients suffering from life-threatening infections caused by resistant bacterial strains.

Nectin Therapeutics Ltd., founded in 2017 and based in Jerusalem, Israel, specializes in the development of monoclonal antibodies targeting members of the Nectin family of receptors and ligands. These antibodies are designed to address immune checkpoint mechanisms that play a crucial role in cancer immunotherapy. By focusing on both solid and hematological malignancies, Nectin Therapeutics aims to create therapies that can overcome the inhibitory pathways utilized by tumors, thereby enhancing the ability of immune cells to eradicate cancer cells. The company's innovative approach seeks to improve patient outcomes in cancer treatment.

Kamari Pharma is focused on developing innovative treatments for unmet medical needs and rare diseases in the field of dermatology. The company has established a bio-pharmaceutical platform that specializes in creating proprietary small molecule inhibitors. This platform employs a scientific approach to address skin conditions that currently lack effective treatments, specifically targeting the underlying causes of serum calcium dysregulation. By doing so, Kamari Pharma aims to provide patients with new therapeutic options for various dermatological issues, thereby improving their quality of life.

CoreBone specializes in the development of a bioactive bone graft material that is suitable for dental, orthopedic, and spinal applications. The company has created a 100% mineral-based graft that incorporates bioactive minerals, such as silicium, into the skeleton of corals during their natural growth process. This innovative approach enhances healing and improves bone connectivity, offering a robust alternative to traditional bone grafts derived from human or animal sources. By providing a material that possesses essential bone-like qualities—such as strength, porosity, and bioactivity—CoreBone aims to promote natural alternatives while raising awareness about the biological risks associated with conventional graft materials. Founded by CEO Ohad Schwartz and CTO Prof. Itzhak Binederman, CoreBone holds patents and extensive expertise in cultivating coral for medical applications.

Alpha Omega is a global company focused on enhancing patient care in neurology and neurosurgery through the development of advanced medical devices. The company specializes in microelectrode recording technology, which facilitates the precise identification of optimal targets for deep brain stimulation electrode implantation. This innovation aims to improve the outcomes of functional neurosurgery and support neuroscience research. With a strong commitment to quality and service, Alpha Omega continuously strives to deliver pioneering solutions that elevate standards in patient care within the neurological field.